Insurance, affordability, FDA approvals, access, health policy, and cost-related IBD news.
Page 1 of 7 · 315 articles
Subtopics
A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...
This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...
An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...
This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.
This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...
An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...
Cure8 found this source from nai500.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.
Long waits for IBD-related surgery were linked to poorer quality of life in this study, especially when waiting exceeded 1 year. That suggests delays could meaningfully affect daily functioning for people with Crohn’s or...
Market shifts — including biosimilars, new biologics, and small-molecule drugs — can affect treatment availability, cost, and prescribing options for people with Crohn’s disease. News about acquisitions and product...
Stories like this highlight how Crohn’s can be misattributed to stress—especially for women—and the emotional, educational, and physical toll of delayed diagnosis and prolonged flares. They can help others recognise...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
Cure8 could only read part of this source from communityimpact.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Access, cost, and policy.
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
Surgical site infection is a common and serious complication after IBD surgery. The paper highlights that antibiotic-resistant bacteria (ESBLs, MRSA) were common in this Saudi cohort and that standard cephalosporin...
The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...
Fundraising events support research, education, advocacy, and direct patient services that can benefit people living with Crohn’s disease and other forms of IBD. A public figure with lived experience being honored can...
Support organizations can offer education, peer connection, mental-health services, advocacy, and programs for children and families that complement medical care. Knowing where to find these resources can help people...
This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...
Based on the title and source metadata, this appears to be an opinion or commentary related to Inflammatory bowel disease and Access, cost, and policy. The original article is from Inflammatory bowel diseases.
Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...
A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...
Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.
Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Access, cost, and policy. The original article is from Gut.
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Mesalamine. The original article is from Drugs - Real World Outcomes.
A sizable minority of people newly diagnosed with IBD—about 1 in 5 with Crohn’s and 1 in 10 with ulcerative colitis—received no IBD-specific drugs within the first year. Understanding who is untreated and why could...
The study suggests that using Advice & Guidance instead of elective referral was associated with a longer time to diagnosis for IBD, which could influence how primary care referral pathways are evaluated or designed.
IBD cases are increasing in Sub-Saharan Africa but care and research remain limited and driven by high-income country priorities. Region-specific research and policy changes could improve diagnosis, treatment access, and...
Modeled cost savings and fewer hospital visits could affect access to infliximab for people with Crohn’s disease and other autoimmune conditions in Jordan, potentially increasing the number of patients who can be treated...
Microbiological differences in Crohn’s-related abscesses could affect empirical antibiotic choices and highlight the importance of culture-directed therapy, especially in patients on immunosuppression who showed higher...
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
Food insecurity was linked with higher odds of having IBD and other GI conditions in a large U.S. survey, and many affected people lacked benefits or cancer screening. This matters because access to sufficient nutritious...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from navlindaily.com.
Based on the title and source metadata, this appears to be an observational study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of the Canadian Association...
Launches of adalimumab and ustekinumab could expand local access to two widely used biologic treatments for Crohn’s disease and ulcerative colitis. Wider availability may affect treatment options and logistics for people...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Crohn's disease, and Biosimilars. The original article is from Arquivos de...
If you or someone you care for uses or may use VELSIPITY (etrasimod) for ulcerative colitis, local manufacturing and priority review in China could improve drug supply, availability, and potentially lower costs. The...
Cure8 found this source from nacionale.com, but the page could not be read reliably yet. It is tagged for Access, cost, and policy. Open the original article for the full details.
People with Crohn’s disease who rely on local specialty pharmacies or critical access hospitals could be indirectly affected by 340B policy: pharmacies may lose money dispensing biologics that carry orphan designations...
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
Standardised care pathways may reduce hospital admissions and help health systems manage the burden of IBD without worsening patient-reported disease control.
CDI is a common and serious complication in people hospitalized with IBD. Understanding whether CDI independently increases the risk of death, ICU care, or surgery — or mainly drives longer stays and higher costs — helps...
Transition to adult care is a high-risk time when adolescents with IBD can experience care gaps and worsened disease control. Understanding which fixed and modifiable factors affect transition can help patients,...
If you or your child has pediatric-onset IBD, much of the care that supports disease management happens between scheduled visits. Recognizing this workload matters for access, clinician time, and policies that affect...
A new Phase 2 study of StemSmart™ could expand treatment options for patients with refractory or fistulising Crohn’s disease if later trials confirm safety and benefit. Appointment of a CRO is an early but important step...
